Retina Associates of Kentucky

Lexington, Kentucky 40509-1827

0 studies enrolling now · 30 studies all time

What they study most

Age Related Macular Degeneration, Age-related Macular Degeneration, Branch Retinal Vein Occlusion, Cataract, Central Retinal Vein Occlusion, Diabetic Macular Edema, Geographic Atrophy, Hemi-retinal Vein Occlusion, Macular Degeneration, Macular Edema, Macular Neovascularization Secondary to Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration

Studies at this site

• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) — Recruiting now
• Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 — Running, not enrolling
• A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products — Running, not enrolling
• 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration — Running, not enrolling
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) — Completed
• A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) — Stopped early
• A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. — Stopped early
• A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) — Completed
• A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) — Completed
• The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) — Completed
• Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) — Completed
• A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration — Completed
• Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) — Stopped early
• Home OCT Fluid Visualization Agreement Study — Status unconfirmed
• Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) — Completed
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration — Completed
• A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema — Completed
• HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device — Completed
• A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) — Stopped early
• Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial — Completed
• Ocriplasmin Research to Better Inform Treatment (ORBIT) — Completed
• HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration — Stopped early
• Age-Related Eye Disease Study 2 (AREDS2) — Completed
• On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) — Status unconfirmed
• Treatment for Presumed Ocular Histoplasmosis — Status unconfirmed
• Genetic Load and Phenotype in Aggressive AMD — Completed
• Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome — Status unconfirmed